Center-Authored Papers

Filters: Author is Richardson, Paul G  [Clear All Filters]
Journal Article
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel J-F, Crawford B, Massaro J, Dhawan R, Gupta S et al..  2008.  Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.. British journal of haematology. 143(4):511-9. Abstract
Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB et al..  2010.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(7):1005-17. Abstract
Cavo M, Rajkumar VS, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M et al..  2011.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.. Blood. 117(23):6063-73. Abstract
Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger WI, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R et al..  2009.  Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.. Blood. 114(9):1729-35. Abstract
Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL et al..  2016.  Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.. Blood. Abstract
Jakubowiak AJ, Benson DM, Bensinger WI, Siegel DSD, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DEH, Singhal AK, Anderson KC.  2012.  Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(16):1965. Abstract
Yee AJ, Bensinger WI, Supko JG, Voorhees PM, Berdeja JG, Richardson PG, Libby EN, Wallace EE, Birrer NE, Burke JN et al..  2016.  Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.. The Lancet. Oncology. 17(11):1569-1578. Abstract